Skip to main navigation
Logo

RSS News Feeds

RSS News Feeds

What is RSS?

Really Simple Syndication (RSS) is a format designed for sharing web content such as headlines. An RSS feed highlights fresh material for you, so you don't have to repeatedly check a site yourself for updates.

How do I use RSS?

To make use of RSS, you'll need an RSS reader, or aggregator. An RSS aggregator can be a stand-alone application, or a plug-in for another program you already use, such as Microsoft Outlook. Some web browsers, such as Firefox and Safari RSS, have RSS readers built in. There are also online aggregators, websites such as My Yahoo or Bloglines that allow you to customize them by adding RSS feeds. Find a downloadable RSS aggregator.

To view a feed in your RSS Aggregator:

  1. Click on the RSS feed that corresponds to the topic that interests you.
  2. Copy the URL.
  3. Paste the URL into your reader.

RSS Feeds

  • General Releases
  • All SEC Filings
  • Form 4 SEC Filings
Investors

    Investor Relations

    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • SEC Filings
    • Stock Information
    • Investor FAQ
    • Contact Us

    Shareholder Tools

    • Email Alerts
    • Print
    • Share

  • Facebook
  • Google
  • LinkedIn
  • Twitter
  • RSS
  • About
    • Management
      • Emil D. Kakkis, M.D., Ph.D.
      • Jayson Dallas, M.D.
      • Dennis Huang
      • Thomas Kassberg
      • Karah Parschauer
      • John Pinion
      • Shalini Sharp
    • Board of Directors
      • Daniel G. Welch
      • Emil D. Kakkis, M.D., Ph.D.
      • William Aliski
      • Deborah Dunsire, M.D.
      • Lars Ekman, M.D., Ph.D.
      • Matthew K. Fust
      • Michael Narachi
      • Clay B. Siegall, Ph.D.
    • Grants & Charitable Contributions
    • Message from BIO
  • Medicines
    • Crysvita®
    • Mepsevii™
  • Pipeline
    • Burosumab for XLH
    • Burosumab for TIO
    • Vestronidase alfa
    • UX007 for FAOD
    • UX007 for Glut1 DS
    • DTX 301 for OTC
    • DTX 401 for GSD1a
    • Presentations & Publications
  • For Patients
    • XLH
    • TIO
    • MPS 7
    • LC-FAOD
    • Glut1 DS
    • OTC
    • GSD1a
    • Access to Investigational Therapies
  • Investors

      Investors

      • Press Releases
      • Events & Presentations
      • Corporate Governance
      • SEC Filings
      • Stock Information
      • Investor FAQ
      • Contact Us
  • Careers
    • Commitment
    • Benefits
    • Interns
    • Jobs
  • Partnering
    • Current Partnerships
  • Contact
  • About
    • Management
      • Emil D. Kakkis, M.D., Ph.D.
      • Jayson Dallas, M.D.
      • Dennis Huang
      • Thomas Kassberg
      • Karah Parschauer
      • John Pinion
      • Shalini Sharp
    • Board of Directors
      • Daniel G. Welch
      • Emil D. Kakkis, M.D., Ph.D.
      • William Aliski
      • Deborah Dunsire, M.D.
      • Lars Ekman, M.D., Ph.D.
      • Matthew K. Fust
      • Michael Narachi
      • Clay B. Siegall, Ph.D.
    • Grants & Charitable Contributions
    • Message from BIO
    • Medicines
      • Crysvita®
      • Mepsevii™
  • Pipeline
    • Burosumab for XLH
    • Burosumab for TIO
    • Vestronidase alfa
    • UX007 for FAOD
    • UX007 for Glut1 DS
    • DTX 301 for OTC
    • DTX 401 for GSD1a
    • Presentations & Publications
  • For Patients
    • XLH
    • TIO
    • MPS 7
    • LC-FAOD
    • Glut1 DS
    • OTC
    • GSD1a
    • Access to Approved Therapies
    • Access to Investigational Therapies
  • Investors

      Investors

      • Press Releases
      • Events & Presentations
      • Corporate Governance
      • SEC Filings
      • Stock Information
      • Investor FAQ
      • Contact Us
  • Careers
    • Commitment
    • Benefits
    • Interns
    • Jobs
    Partnering
    • Current Partnerships
    Contact
    • Driving Directions
  • Privacy Policy
© 2018 Ultragenyx Pharmaceutical Inc.Website Design: Hane Chow, Inc.
  • Privacy Policy